SunLink Health Systems (SSY) 10-Q 13 Feb 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 13, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		6,978,769
Entity File Number	1-12607
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	31-0621189
Entity Address, Address Line One	900 Circle 75 Parkway
Entity Address, Address Line Two	Suite 1120
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30339
City Area Code	770
Local Phone Number	933-7000
Document Quarterly Report	true
Document Transition Report	false
Common Stock [Member]
Document Information [Line Items]
Trading Symbol	SSY
Title of 12(b) Security	Common Shares without par value
Security Exchange Name	NYSEAMER
Preferred Share Purchase Rights [Member]
Document Information [Line Items]
No Trading Symbol Flag	true
Title of 12(b) Security	Preferred Share Purchase Rights

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Current Assets:
Cash and cash equivalents	$ 4,607	$ 7,742
Receivables - net	5,627	4,715
Inventory	2,056	2,016
Prepaid expense and other assets	2,094	2,185
Total current assets	14,384	16,658
Property, plant and equipment, at cost	20,267	19,520
Less accumulated depreciation	14,855	14,277
Property, plant and equipment - net	5,412	5,243
Noncurrent Assets:
Intangible assets - net	1,295	1,353
Income tax receivable	153	153
Assets held for sale	0	249
Right of use assets	1,194	0
Other noncurrent assets	385	763
Total noncurrent assets	3,027	2,518
TOTAL ASSETS	22,823	24,419
Current liabilities:
Accounts payable	1,647	1,564
Current maturities of long-term debt, net of debt issuance costs	327	2,836
Accrued payroll and related taxes	1,885	1,960
Accrued sales tax	1,132	843
Current operating lease liabilties	455	0
Other accrued expenses	994	1,207
Total current liabilities	6,440	8,410
Long-Term Liabilities
Long-term debt	110	127
Noncurrent liability for professional liability risks	623	705
Long-term operating lease liabilities	741	0
Other noncurrent liabilities	147	134
Total long-term liabilities	1,621	966
Commitment and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Issued and outstanding, 6,983 shares at December 31, 2019 and 6,987 at June 30, 2019	3,492	3,493
Additional paid-in capital	10,768	10,745
Retained earnings	755	1,058
Accumulated other comprehensive loss	(253)	(253)
Total Shareholders’ Equity	14,762	15,043
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 22,823	$ 24,419

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Statement Of Financial Position [Abstract]
Preferred shares, authorized	2,000,000	2,000,000
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	6,983,000	6,987,000
Common shares, outstanding	6,983,000	6,987,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Net revenues	$ 12,805	$ 12,151	$ 24,457	$ 22,358
Costs and Expenses
Salaries, wages and benefits	4,849	4,620	9,758	9,294
Supplies	334	324	653	612
Other operating expenses	994	982	2,097	1,995
Rent and lease expense	147	168	306	303
Depreciation and amortization	350	351	685	689
Operating Profit (Loss)	281	(134)	61	(861)
Other Income (Expense):
Gains on sale of assets	86	452	193	454
Loss on extinguishment of debt	(160)	0	(160)	0
Interest expense, net	(4)	(60)	(34)	(121)
Earnings (Loss) from Continuing Operations before income taxes	203	258	60	(528)
Income Tax Benefit	0	0	0	0
Income (Loss) from Continuing Operations	203	258	60	(528)
Income (Loss) from Discontinued Operations, net of tax	(245)	47	(363)	(47)
Net Income (Loss)	(42)	305	(303)	(575)
Other comprehensive income	0	0	0	0
Comprehensive Earnings (Loss)	$ (42)	$ 305	$ (303)	$ (575)
Continuing Operations:
Basic	$ 0.03	$ 0.04	$ 0.01	$ (0.07)
Diluted	0.03	0.04	0.01	(0.07)
Discontinued Operations:
Basic	(0.04)	0.01	(0.05)	(0.01)
Diluted	(0.04)	0.01	(0.05)	(0.01)
Net Earnings (Loss):
Basic	(0.01)	0.04	(0.04)	(0.08)
Diluted	$ (0.01)	$ 0.04	$ (0.04)	$ (0.08)
Weighted-Average Common Shares Outstanding:
Basic	6,986	7,271	6,986	7,309
Diluted	6,992	7,278	7,012	7,309
Product [Member]
Costs and Expenses
Cost of goods sold	$ 5,097	$ 5,255	$ 9,441	$ 9,172
Service [Member]
Costs and Expenses
Cost of goods sold	$ 753	$ 585	$ 1,456	$ 1,154

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement Of Cash Flows [Abstract]
Net Cash Provided by (Used in) Operating Activities	$ (443)	$ 144
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations	(548)	(644)
Expenditures for property, plant and equipment - discontinued operations	0	(50)
Proceeds from sale of other assets	558	937
Net Cash Provided by Investing Activities	10	243
Cash Flows Used in Financing Activities:
Payments on long-term debt	(2,698)	(138)
Repurchase of common shares	(4)	(379)
Net Cash Used in Financing Activities	(2,702)	(517)
Net Decrease in Cash and Cash Equivalents	(3,135)	(130)
Cash and Cash Equivalents Beginning of Period	7,742	3,456
Cash and Cash Equivalents End of Period	4,607	3,326
Cash Paid for:
Interest	61	109
Income taxes	(43)	0
Non-cash investing and financing activities:
Assets acquired under capital lease obligations	0	176
Assets acquired in exchange for note receivable	371	0
Right-of-use assets obtained in exchange for lease liabilities	$ 1,448	$ 0

Basis of Presentation and Adopt

Basis of Presentation and Adoption of Recently Issued Accounting Standards	6 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and Adoption of Recently Issued Accounting Standards	Note 1. –Basis of Presentation and Adoption of Recently Issued Accounting Standards Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2019 and for the three and six month periods ended December 31, 2019 and 2018 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2019 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed with the SEC on September 27, 2019. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any particular asset, business or property. Each operation and business described in this filing is owned and operated by a distinct and indirect subsidiary of SunLink Health System, Inc. Adoption of Recently Issued Accounting Standards ASC 842, “Leases” – On July 1, 2019, the Company adopted cumulative accounting standard updates initially issued by the Financial Accounting Standards Board (“FASB”) that amend the accounting for leases and are codified as Accounting Standards Codification (“ASC”) 842. These lease accounting changes require operating leases be recorded on the balance sheet through the recognition of a liability for the discounted present value of future fixed lease payments and a corresponding right-of-use (“ROU”) asset. The Company’s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less which do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded on the balance sheet; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. Our lease agreements do not contain any material residual value guarantees. The Company elected the amended transition requirements allowed for by the FASB in Accounting Standards Update (“ASU”) 2018-11, which provides relief from requirements to recast prior comparative periods under ASC 842. As a result, the prior year comparative financial statements have not been restated to reflect the adoption of ASC 842. Additionally, the Company elected the “package of practical expedients” available in ASC 842 whereby an entity need not reassess expired contracts for lease identification or classification as a finance or operating lease, or reassess the initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. Certain of the Company’s lease agreements have lease and non-lease components, which for the majority of leases the Company accounts for separately when the actual lease and non-lease components are determinable. For equipment leases with immaterial non-lease components incorporated into the fixed rent payment, the Company accounts for the lease and non-lease components as a single lease component in determining the lease payment. The adoption of ASC 842 on July 1, 2019 resulted in the Company recording $1,423 of operating lease liabilities and an equal amount of ROU assets with no impact on retained earnings. The adoption did not have a material impact on the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the three and six months ended December 31, 2019.

Business Operations

Business Operations	6 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business Operations	Note 2. – Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s subsidiaries’ businesses are composed of two business segments: Healthcare Services • A subsidiary which owns and operates Trace Regional Hospital and Floy Dyer Nursing Home (“Trace”), an 84 licensed-bed acute care hospital, located in Houston, Mississippi, which includes an 18-bed geriatric psychology unit (“GPU”), and a 66-bed nursing home. This facility focuses primarily on senior healthcare services. • A subsidiary, SunLink Health Systems Technology (SHS Technology), based in Atlanta, Georgia, which provides information technology (IT) services to outside customers and to SunLink subsidiaries. • A subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi. Pharmacy The Pharmacy segment is composed of four operational areas which are conducted primarily in rural markets in Louisiana: • Retail pharmacy products and services, provided by a retail pharmacy. • Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities. • Non-institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings including private residential homes. • Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care. SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of our SunLink ScriptsRx, LLC subsidiary. .

Discontinued Operations

Discontinued Operations	6 Months Ended
	Dec. 31, 2019
Discontinued Operations And Disposal Groups [Abstract]
Discontinued Operations	Note 3. – Discontinued Operations All the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation. Results for all the businesses included in discontinued operations are presented in the following table: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Net Revenues: Parkside Nursing Home $ 3 $ 2,072 $ 17 $ 3,917 Sold Hospitals 10 6 20 13 $ 13 $ 2,078 $ 37 $ 3,930 Earnings (Loss) before income taxes: Parkside Nursing Home $ (120 ) $ 122 $ (180 ) $ 64 Sold Hospitals (82 ) (51 ) (115 ) (62 ) Life sciences and engineering (43 ) (24 ) (68 ) (49 ) Earnings (Loss) from discontinued operations before income taxes (245 ) 47 (363 ) (47 ) Income tax expense 0 0 0 0 Earnings (Loss) from discontinued operations $ (245 ) $ 47 $ (363 ) $ (47 ) Parkside Nursing Home — On March 17, 2019, a subsidiary of the Company sold its Parkside Ellijay Nursing Home and related real estate for $7,300 subject to adjustment for the book value of certain assets and liabilities on the sale date. The pre-tax gain on the sale was $2,136, which was recognized in the fiscal year ended June 30, 2019. The net proceeds of the sale were retained for working capital and general corporate purposes. Sold Hospitals – Subsidiaries of the Company have sold substantially all the assets of four hospitals (“Sold Hospitals”) during the period July 2, 2012 to August 19, 2016. The loss before income taxes of the Sold Hospitals results primarily from the effects of retained professional liability insurance and claims expenses. Life Sciences and Engineering Segment —SunLink retained a defined benefit retirement plan which covered substantially all the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and six months ended December 31, 2019 and 2018, respectively. The components of pension expense for the three months ended December 31, 2019 and 2018, respectively, were as follows: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Interest Cost $ 10 $ 14 $ 24 $ 28 Expected return on assets (8 ) (9 ) (17 ) (18 ) Amortization of prior service cost 41 19 61 39 Net pension expense $ 43 $ 24 $ 68 $ 49 SunLink contributed $66 to the plan in the six months ended December 31, 2019 and expects to contribute an additional $66 during the remaining two fiscal quarters of the fiscal year ending June 30, 2020.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Dec. 31, 2019
Federal Home Loan Banks [Abstract]
Shareholders' Equity	Note 4. – Shareholders’ Equity 2019-2020 Common Share Repurchase Program – On October 8, 2019, the Company announced a share repurchase program (“2019-2020 Program”) approved by its Board of Directors which authorizes the Company to purchase up to $750 of its common shares in the open market. As of December 31, 2019, a total of 3,814 shares have been repurchased at a cost of approximately $4. The chart below shows by month the total shares repurchased and average price per share paid for the 2019-2020 Program through December 31, 2019. As of the date of this filing, the Company has repurchased 8,086 shares at a cost of approximately $9. On January 31, 2020, the Company announced its Board of Directors had extended the terminate date of the 2019-2020 Program to June 1, 2020, unless it further extended or earlier terminated by the Company. Total Shares Average Price Purchased Per Share Paid November 2019 935 $ 1.17 December 2019 2,879 1.18 Total 3,814 $ 1.17 2018 Common Share Repurchase Program – On November 29, 2018, the Company announced a share repurchase program (“2018 Program”) approved by its Board of Directors, which authorized the Company to purchase up to 300,000 shares of its common shares. On December 13, 2018, the Company announced it had purchased the 300,000 shares authorized under the 2018 Program, and that its Board of Directors had authorized an additional 450,000 shares to be purchased under the 2018 Program. As of October 3, 2019, the 2018 Program termination date, a total of 359,959 shares were repurchased at a cost of approximately $372, excluding fees and expenses relating to the offer Total Shares Average Price Purchased Per Share Paid November 2018 1,235 $ 1.14 December 2018 358,724 1.03 Total 359,959 $ 1.03 Stock-Based Compensation – For the three months ended December 31, 2019 and 2018, the Company recognized no stock-based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2019 and 2018, the Company recognized $27 and $1, respectively, in stock-based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option-pricing model. There were 50,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2019, and no shares granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2018.

Revenue and Accounts Receivable

Revenue and Accounts Receivables	6 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Revenue And Accounts Receivable	Note 5. – Revenue and Accounts Receivables Revenues by payor were as follows for the three months ended December 31, 2019 and 2018: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Medicare $ 5,295 $ 3,372 10,359 7,582 Medicaid 4,061 5,149 7,244 8,147 Retail and Institutional Pharmacy 1,442 1,642 3,141 3,275 Managed Care & Other Insurance 1,877 1,751 3,396 2,872 Self-pay 90 185 238 384 Rent 8 16 18 30 Other 32 36 61 68 Total Net Revenues $ 12,805 $ 12,151 $ 24,457 $ 22,358 Summary information for accounts receivable is as follows: December 31, 2019 June 30, 2019 Accounts receivable (net of contractual allowances) $ 6,275 $ 5,230 Less allowance for concession adjustments (648 ) (515 ) Patient and customer accounts receivable - net $ 5,627 $ 4,715 The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three months ended December 31, 2019 and 2018: Three Months Ended December 31, 2019 Healthcare Services Pharmacy Total Balance at October 1, 2019 $ 286 $ 176 $ 462 Additions recognized as a reduction to revenues: Continuing Operations 361 171 532 Discontinued Operations (14 ) 0 (14 ) Accounts written off, net of recoveries (240 ) (92 ) (332 ) Balance at December 31, 2019 $ 393 $ 255 $ 648 Six Months Ended December 31, 2019 Healthcare Services Pharmacy Total Balance at July 1, 2019 $ 331 $ 184 $ 515 Additions recognized as a reduction to revenues: Continuing Operations 410 234 644 Discontinued Operations (34 ) 0 (34 ) Accounts written off, net of recoveries (314 ) (163 ) (477 ) Balance at December 31, 2019 $ 393 $ 255 $ 648 Three Months Ended December 31, 2018 Healthcare Services Pharmacy Total Balance at October 1, 2018 $ 185 $ 266 $ 451 Additions recognized as a reduction to revenues: Continuing Operations 126 96 222 Discontinued Operations (15 ) 0 (15 ) Accounts written off, net of recoveries (65 ) (134 ) (199 ) Balance at December 31, 2018 $ 231 $ 228 $ 459 Six months Ended December 31, 2018 Healthcare Services Pharmacy Total Balance at July 1, 2018 $ 253 $ 276 $ 529 Additions recognized as a reduction to revenues: Continuing Operations 173 199 372 Discontinued Operations (34 ) 0 (34 ) Accounts written off, net of recoveries (161 ) (247 ) (408 ) Balance at December 31, 2018 $ 231 $ 228 $ 459

Intangible Assets

Intangible Assets	6 Months Ended
	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6. – Intangible Assets Intangibles consist of the following, net of amortization: December 31, 2019 June 30, 2019 Pharmacy Segment Intangibles Trade Name (non-amortizing) $ 1,180 $ 1,180 Customer Relationships 1,089 1,089 Medicare License 623 623 2,892 2,892 Accumulated Amortization (1,597 ) (1,539 ) Net Intangibles $ 1,295 $ 1,353 Amortization expense was $29 and $29 for the three months ended December 31, 2019 and 2018, respectively. Amortization expense was $58 and $58 for the six months ended December 31, 2019 and 2018, respectively.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Debt	Note 7. – Long-Term Debt Long-term debt consisted of the following: December 31, 2019 June 30, 2019 Trace RDA Loan $ 316 $ 2,999 Capital Lease 143 159 Less unamortized debt issuance costs (22 ) (195 ) Less current maturities (327 ) (2,836 ) Long-term Debt $ 110 $ 127 Trace RDA Loan— Southern Health Corporation of Houston, Inc. (“Trace”) a wholly owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement (“Trace RDA Loan”) with a bank, dated as of July 5, 2012. The Trace RDA Loan has a term of 15 years with level monthly payments of principal and interest until repaid. The Trace RDA Loan interest rate is the prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%, (5.75% at December 31, 2019). The Trace RDA Loan is collateralized by real estate and equipment of Trace and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program On October 7, 2019, the Company made a $2,500 pre-payment on the Trace RDA Loan. The pre-payment was made with cash on hand. The Company recorded a non-cash loss on early extinguishment of debt relating to the pre-payment of $160 during the three and six months ended December 31, 2019. Based on the current Trace RDA Loan amortization schedule, the outstanding balance of the Loan is required to be repaid in October 2020. Accordingly, the outstanding loan amount at December 31, 2019 is classified as a current liability. On February 12, 2020, the Company paid the outstanding balance of the Trace RDA Loan. See Note 16. – Subsequent Events. The Trace RDA Loan contains various covenants, terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants and is guaranteed by SunLink. The covenants include financial covenants measured on a quarterly basis that require Trace to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge ratio, and funded debt to EBITDA, all as defined in the Trace RDA Loan. At June 30, 2019, Trace was not in compliance with the debt service coverage, fixed charge coverage and funded debt to EBITDA ratios. The Company had discussed with the lender a waiver of this non-compliance, but a waiver of non-compliance has not been received as of the date of filing this report. Trace was in compliance with the covenants as measured at September 30, 2019 and December 31, 2019. No event of default has been declared by the lender as of the date of the filing of this report nor is such a declaration currently anticipated.

Income Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 8. – Income Taxes Income tax benefit of $0 ($0 federal and state tax expense) and income tax expense of $0 ($0 federal tax and state tax expense) was recorded for continuing operations for the three and six months ended December 31, 2019 and 2018, respectively. In accordance with the Financial Accounting Standards Board Accounting Standards Codification (‘ASC”) 740, we evaluate our deferred taxes quarterly to determine if adjustments to our valuation allowance are required based on the consideration of available positive and negative evidence using a “more likely than not” standard with respect to whether deferred tax assets will be realized. Our evaluation considers, among other factors, our historical operating results, our expectation of future results of operations, the duration of applicable statuary carryforward periods and conditions of the healthcare industry. The ultimate realization of our deferred tax assets depends primarily on our ability to generate future taxable income during the periods in which the related temporary differences in the financial basis and the tax basis of the assets become deductible. The value of our deferred tax assets will depend on applicable income tax rates. At December 31, 2019, consistent with the above process, we evaluated the need for a valuation against our deferred tax assets and determined that it was more likely than not that none of our deferred tax assets would be realized. As a result, in accordance with ASC 740, we recognized a valuation allowance of $8,674 against the deferred tax asset so that there is no net long-term deferred income tax asset or liability at December 31, 2019. We conducted our evaluation by considering available positive and negative evidence to determine our ability to realize our deferred tax assets. In our evaluation, we gave more significant weight to evidence that was objective in nature as compared to subjective evidence. Also, more significant weight was given to evidence that directly related to our current financial performance as compared to less current evidence and future plans. The principal negative evidence that led us to determine at December 31, 2019 that all the deferred tax assets should have full valuation allowances was the three-year cumulative pre-tax loss from continuing operations as well as the underlying negative business conditions for rural healthcare businesses in which our Healthcare Services Segment businesses operate. For Federal income tax purposes, at December 31, 2019, the Company had approximately $19,200 of estimated net operating loss carry-forwards available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. These net operating loss carryforwards expire primarily in fiscal 2023 through fiscal 2038; however, with the enactment of the TCJA on December 22, 2017, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 now have no expiration date. The Company’s returns for the periods prior to the fiscal year ended June 30, 2016 are no longer subject to potential federal and state income tax examination.

Leases

Leases	6 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	Note 9. – Leases The Company has operating leases and a financing lease relating to its pharmacy operations, medical office buildings, certain medical equipment and office equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs. Variable lease costs also include escalating rent payments that are not fixed at commencement but are based on an index determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. Some leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rental rates. Leases may also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term. The components of lease cost and rent expense for the three and six months ended December 31, 2019 are as follows: Three Months Ended Six Months Ended Lease Cost December 31, 2019 December 31, 2019 Operating lease cost: Operating lease cost $ 143 $ 290 Short-term rent expense 4 15 Variable lease cost 0 1 Total operating lease cost $ 147 $ 306 Finance lease cost: Amortization right-of-use assets $ 9 $ 18 Interest on finance lease liabilities 2 5 Total finance lease cost $ 11 $ 23 Supplemental balance sheet information to leases was as follows: As of Balance Sheet Classifications December 31, 2019 Operating Leases: Operating Lease ROU Assets ROU Assets $ 1,194 Finance Leases: Finance Lease ROU Assets Property, plant and equipment 203 Accumulated amortization Accumulated depreciation 29 Current finance lease liabilities Current maturities of long-term debt 33 Long-term finance lease liabilities Long-term debt 110 Supplemental cash flow and other information related to leases as of and for the three and six months ended December 31, 2019 are as follows: Three Months Ended Six Months Ended Other information December 31, 2019 December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 150 $ 289 Operating cash flows from finance leases 2 5 Financing cash flow from finance leases 8 16 Right-of-use assets obtained in exchange for new finance lease liabilities 0 0 Right-of-use assets obtained in exchange for new operating lease liabilities 9 1,448 Weighted-average remaining lease term: Operating leases 3.91 years 3.91 years Finance leases 3.77 years 3.77 years Weighted-average discount rate: Operating leases 6.54 % 6.54 % Finance leases 5.53 % 5.53 % Commitments relating to non-cancellable operating and finance leases as of December 31, 2019 for each of the next five years and thereafter are as follows: Payments due within Operating Leases Finance Leases 1 year $ 506 $ 42 2 years 352 42 3 years 146 42 4 years 103 37 5+ years 222 0 Total minimum future payments 1,329 163 Less: Imputed interest (133 ) (20 ) Total liabilities 1,196 143 Less: Current portion (455 ) (33 ) Long-term liabilities $ 741 $ 110

Accrued Sales Tax

Accrued Sales Tax	6 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued Sales Tax	Note 10. – Accrued Sales Tax During the fiscal year ended June 30, 2019, the Pharmacy segment business amended its sales tax position to exempt from sales tax consideration any revenue from sales of products and services to beneficiaries of government insurance programs to the extent reimbursed by the administrators of such programs. No sales taxes are included in the related reimbursement received from sales of such products and services from the government payers’ insurance programs. The Company is in the process of filing amended sales tax returns for periods still available to file such amended returns under the applicable statutes of limitations, and it intends to file amended sales tax returns for all such prior periods. Refunds have been received from two taxing authorities in the amounts claimed in such amended returns. Amounts claimed for these two taxing authorities believed to be estimable and probable of collection have been recorded in the quarter ended December 31, 2019 in the amount of $267. The subsidiary’s position with other local taxing authorities has not yet been determined probable of collection; therefore, the subsidiary has continued to accrue the amounts for sales tax estimates that it believes would be payable if its amended returns position is challenged and the Company does not prevail. The sales tax accrued at December 31, 2019 is $1,132 compared to $843 at June 30, 2019.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. – Commitments and Contingencies Contractual obligations, commitments and contingencies related to outstanding debt and interest on outstanding debt from continuing operations at December 31, 2019 were as follows: Payments due within: Long-Term Debt Interest on Outstanding Debt 1 year $ 349 $ 16 2 years 35 6 3 years 38 4 4 years 37 1 5+ years 0 0 $ 459 $ 27 Contingencies do not reflect potential amounts for claims, litigation and other uncertainties, which matters are not probable or cannot be estimated, such as for certain professional liabilities and contract matters, including those relating to prior assets sales.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. – Related Party Transactions A director of the Company is a member of a law firm which provides services to SunLink. The Company expensed an aggregate of $62 and $59 for legal services to this law firm in the three months ended December 31, 2019 and 2018, respectively. The Company expensed an aggregate of $180 and $135 for legal services to this law firm in the six months ended December 31, 2019 and 2018, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2019 and June 30, 2019 is $19 and $47, respectively, of amounts payable to this law firm.

Asset Sales

Asset Sales	6 Months Ended
	Dec. 31, 2019
Asset Sales [Abstract]
Asset Sales	Note 13. – Asset Sales On September 9, 2019, the Company sold approximately 11.4 acres of undeveloped land in Fulton, MO. After expenses, the Company received net proceeds from the sale of $348, which was retained for working capital and general corporate purposes. The pre-tax gain on the sale of property was $100 and is included in the Company’s results for the six months ended December 31, 2019. On December 20, 2019, the Company sold a medical office building and approximately 4 acres of land in Clanton, AL. After expenses, the Company received net proceeds from the sale of $204, which was retained for working capital and general corporate purposes. The pre-tax gain on the sale of property was $86 and is included in the Company’s three and six months results ended December 31, 2019. On October 11, 2018, the Company sold a vacant medical office building and approximately 2 adjacent acres of undeveloped land in Dahlonega, GA. After expenses, the Company received net proceeds from the sale of $935, which was retained for working capital and general corporate purposes. The pre-tax gain on the sale of property of $452 is included in the Company’s three and six months results ended December 31, 2018.

Land Acquisition

Land Acquisition	6 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Land Acquisition	Note 14. – Land Acquisition In conjunction with the 2014 settlement of a lawsuit, the Company received a five-year promissory note maturing in October 2019. The note was secured by a non-recourse mortgage on approximately 24.74 acres of real property in Ellijay, Georgia. The terms of the Note and mortgage provided that if the owner of the real property did not pay the note at maturity, the Company could foreclose and take title to the property. The real property was conveyed to the Company on November 1, 2019 by deed in lieu of payment of the note. The market value of the note was estimated to be $371 which was based on a September 2019 appraisal of the property and the land was valued at $371 at the conveyance of the property by the Company.

Financial Information by Segmen

Financial Information by Segment	6 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Financial Information by Segment	Note 15. – Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Services and Pharmacy. We evaluate performance of our operating segments based on revenue and operating profit (loss). At the beginning of the current fiscal year, the Company modified the approach to certain assets, and expense allocations to calculate segment assets, operating profit and depreciation and amortization. All prior year amounts have been changed to consistently apply the changed allocation method used in the current year. Segment information as of December 31, 2019 and 2018 and for the three and six months then ended is as follows: Healthcare Services Pharmacy Corporate and Other Total As of and for the three months ended December 31, 2019, Net revenues from external customers $ 4,314 $ 8,491 $ 0 $ 12,805 Operating profit (loss) 297 518 (534 ) 281 Depreciation and amortization 89 260 1 350 Assets 7,339 9,892 5,592 22,823 Expenditures for property, plant and equipment 17 280 0 297 As of and for the three months ended December 31, 2018, Net revenues from external customers $ 4,081 $ 8,070 $ 0 $ 12,151 Operating profit (loss) 326 61 (521 ) (134 ) Depreciation and amortization 85 266 0 351 Assets 13,069 8,605 4,052 25,726 Expenditures for property, plant and equipment 59 173 0 232 As of and for the six months ended December 31, 2019, Net revenues from external customers $ 8,546 $ 15,911 $ 0 $ 24,457 Operating profit (loss) 465 781 (1,185 ) 61 Depreciation and amortization 177 506 2 685 Assets 7,339 9,892 5,592 22,823 Expenditures for property, plant and equipment 55 493 0 548 As of and for the six months ended December 31, 2018, Net revenues from external customers $ 7,772 $ 14,586 $ 0 $ 22,358 Operating profit (loss) 110 4 (975 ) (861 ) Depreciation and amortization 166 522 1 689 Assets 13,069 8,605 4,052 25,726 Expenditures for property, plant and equipment 202 442 0 644

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	N ote 16. – Subsequent Events Payment of Trace RDA Loan outstanding balance– On February 12, 2020, the Company paid the total $278 outstanding balance of the Trace RDA loan. The pre-payment was made with cash on hand. The Company expects to report, in the quarter ended March 31, 2020, a non-cash loss on early extinguishment of debt relating to the pre-payment of approximately $20.

Basis of Presentation and Ado_2

Basis of Presentation and Adoption of Recently Issued Accounting Standards (Policies)	6 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2019 and for the three and six month periods ended December 31, 2019 and 2018 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2019 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed with the SEC on September 27, 2019. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2019 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. Throughout these notes to the consolidated financial statements, SunLink Health Systems, Inc., and its consolidated subsidiaries are referred to on a collective basis as “SunLink”, “we”, “our”, “ours”, “us” or the “Company.” This drafting style is not meant to indicate that the publicly traded Company or any particular subsidiary of the Company owns or operates any particular asset, business or property. Each operation and business described in this filing is owned and operated by a distinct and indirect subsidiary of SunLink Health System, Inc.
Adoption of Recently Issued Accounting Standards	Adoption of Recently Issued Accounting Standards ASC 842, “Leases” – On July 1, 2019, the Company adopted cumulative accounting standard updates initially issued by the Financial Accounting Standards Board (“FASB”) that amend the accounting for leases and are codified as Accounting Standards Codification (“ASC”) 842. These lease accounting changes require operating leases be recorded on the balance sheet through the recognition of a liability for the discounted present value of future fixed lease payments and a corresponding right-of-use (“ROU”) asset. The Company’s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less which do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded on the balance sheet; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. Our lease agreements do not contain any material residual value guarantees. The Company elected the amended transition requirements allowed for by the FASB in Accounting Standards Update (“ASU”) 2018-11, which provides relief from requirements to recast prior comparative periods under ASC 842. As a result, the prior year comparative financial statements have not been restated to reflect the adoption of ASC 842. Additionally, the Company elected the “package of practical expedients” available in ASC 842 whereby an entity need not reassess expired contracts for lease identification or classification as a finance or operating lease, or reassess the initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. Certain of the Company’s lease agreements have lease and non-lease components, which for the majority of leases the Company accounts for separately when the actual lease and non-lease components are determinable. For equipment leases with immaterial non-lease components incorporated into the fixed rent payment, the Company accounts for the lease and non-lease components as a single lease component in determining the lease payment. The adoption of ASC 842 on July 1, 2019 resulted in the Company recording $1,423 of operating lease liabilities and an equal amount of ROU assets with no impact on retained earnings. The adoption did not have a material impact on the Company’s condensed consolidated statement of operations or condensed consolidated statement of cash flows for the three and six months ended December 31, 2019.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Dec. 31, 2019
Discontinued Operations And Disposal Groups [Abstract]
Schedule of Discontinued Operations	Results for all the businesses included in discontinued operations are presented in the following table: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Net Revenues: Parkside Nursing Home $ 3 $ 2,072 $ 17 $ 3,917 Sold Hospitals 10 6 20 13 $ 13 $ 2,078 $ 37 $ 3,930 Earnings (Loss) before income taxes: Parkside Nursing Home $ (120 ) $ 122 $ (180 ) $ 64 Sold Hospitals (82 ) (51 ) (115 ) (62 ) Life sciences and engineering (43 ) (24 ) (68 ) (49 ) Earnings (Loss) from discontinued operations before income taxes (245 ) 47 (363 ) (47 ) Income tax expense 0 0 0 0 Earnings (Loss) from discontinued operations $ (245 ) $ 47 $ (363 ) $ (47 )
Components of Pension Expense	The components of pension expense for the three months ended December 31, 2019 and 2018, respectively, were as follows: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Interest Cost $ 10 $ 14 $ 24 $ 28 Expected return on assets (8 ) (9 ) (17 ) (18 ) Amortization of prior service cost 41 19 61 39 Net pension expense $ 43 $ 24 $ 68 $ 49

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2019
Federal Home Loan Banks [Abstract]
Summary of Total Share Repurchased and Average Price Per Share Paid for the Program	The chart below shows by month the total shares repurchased and average price per share paid for the 2019-2020 Program through December 31, 2019. As of the date of this filing, the Company has repurchased 8,086 shares at a cost of approximately $9. Total Shares Average Price Purchased Per Share Paid November 2019 935 $ 1.17 December 2019 2,879 1.18 Total 3,814 $ 1.17 Total Shares Average Price Purchased Per Share Paid November 2018 1,235 $ 1.14 December 2018 358,724 1.03 Total 359,959 $ 1.03

Revenue and Accounts Receivab_2

Revenue and Accounts Receivables (Tables)	6 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Summary of Revenues by Payor	Revenues by payor were as follows for the three months ended December 31, 2019 and 2018: Three Months Ended Six Months Ended December 31, December 31, 2019 2018 2019 2018 Medicare $ 5,295 $ 3,372 10,359 7,582 Medicaid 4,061 5,149 7,244 8,147 Retail and Institutional Pharmacy 1,442 1,642 3,141 3,275 Managed Care & Other Insurance 1,877 1,751 3,396 2,872 Self-pay 90 185 238 384 Rent 8 16 18 30 Other 32 36 61 68 Total Net Revenues $ 12,805 $ 12,151 $ 24,457 $ 22,358
Summary Information for Accounts Receivable	Summary information for accounts receivable is as follows: December 31, 2019 June 30, 2019 Accounts receivable (net of contractual allowances) $ 6,275 $ 5,230 Less allowance for concession adjustments (648 ) (515 ) Patient and customer accounts receivable - net $ 5,627 $ 4,715
Summary of Allowance for Concession Adjustments	The following is a summary of the activity in the allowance for concession adjustments for the Healthcare Services Segment and the Pharmacy Segment for the three months ended December 31, 2019 and 2018: Three Months Ended December 31, 2019 Healthcare Services Pharmacy Total Balance at October 1, 2019 $ 286 $ 176 $ 462 Additions recognized as a reduction to revenues: Continuing Operations 361 171 532 Discontinued Operations (14 ) 0 (14 ) Accounts written off, net of recoveries (240 ) (92 ) (332 ) Balance at December 31, 2019 $ 393 $ 255 $ 648 Six Months Ended December 31, 2019 Healthcare Services Pharmacy Total Balance at July 1, 2019 $ 331 $ 184 $ 515 Additions recognized as a reduction to revenues: Continuing Operations 410 234 644 Discontinued Operations (34 ) 0 (34 ) Accounts written off, net of recoveries (314 ) (163 ) (477 ) Balance at December 31, 2019 $ 393 $ 255 $ 648 Three Months Ended December 31, 2018 Healthcare Services Pharmacy Total Balance at October 1, 2018 $ 185 $ 266 $ 451 Additions recognized as a reduction to revenues: Continuing Operations 126 96 222 Discontinued Operations (15 ) 0 (15 ) Accounts written off, net of recoveries (65 ) (134 ) (199 ) Balance at December 31, 2018 $ 231 $ 228 $ 459 Six months Ended December 31, 2018 Healthcare Services Pharmacy Total Balance at July 1, 2018 $ 253 $ 276 $ 529 Additions recognized as a reduction to revenues: Continuing Operations 173 199 372 Discontinued Operations (34 ) 0 (34 ) Accounts written off, net of recoveries (161 ) (247 ) (408 ) Balance at December 31, 2018 $ 231 $ 228 $ 459

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangibles consist of the following, net of amortization: December 31, 2019 June 30, 2019 Pharmacy Segment Intangibles Trade Name (non-amortizing) $ 1,180 $ 1,180 Customer Relationships 1,089 1,089 Medicare License 623 623 2,892 2,892 Accumulated Amortization (1,597 ) (1,539 ) Net Intangibles $ 1,295 $ 1,353

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Summary of Long-Term Debt	Long-term debt consisted of the following: December 31, 2019 June 30, 2019 Trace RDA Loan $ 316 $ 2,999 Capital Lease 143 159 Less unamortized debt issuance costs (22 ) (195 ) Less current maturities (327 ) (2,836 ) Long-term Debt $ 110 $ 127

Leases (Tables)

Leases (Tables)	6 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Components of Lease Cost and Rent Expense	The components of lease cost and rent expense for the three and six months ended December 31, 2019 are as follows: Three Months Ended Six Months Ended Lease Cost December 31, 2019 December 31, 2019 Operating lease cost: Operating lease cost $ 143 $ 290 Short-term rent expense 4 15 Variable lease cost 0 1 Total operating lease cost $ 147 $ 306 Finance lease cost: Amortization right-of-use assets $ 9 $ 18 Interest on finance lease liabilities 2 5 Total finance lease cost $ 11 $ 23
Summary of Supplemental Balance Sheet Information	Supplemental balance sheet information to leases was as follows: As of Balance Sheet Classifications December 31, 2019 Operating Leases: Operating Lease ROU Assets ROU Assets $ 1,194 Finance Leases: Finance Lease ROU Assets Property, plant and equipment 203 Accumulated amortization Accumulated depreciation 29 Current finance lease liabilities Current maturities of long-term debt 33 Long-term finance lease liabilities Long-term debt 110
Summary of Supplemental Cash Flow and Other Information Related to Leases	Supplemental cash flow and other information related to leases as of and for the three and six months ended December 31, 2019 are as follows: Three Months Ended Six Months Ended Other information December 31, 2019 December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 150 $ 289 Operating cash flows from finance leases 2 5 Financing cash flow from finance leases 8 16 Right-of-use assets obtained in exchange for new finance lease liabilities 0 0 Right-of-use assets obtained in exchange for new operating lease liabilities 9 1,448 Weighted-average remaining lease term: Operating leases 3.91 years 3.91 years Finance leases 3.77 years 3.77 years Weighted-average discount rate: Operating leases 6.54 % 6.54 % Finance leases 5.53 % 5.53 %
Summary of Non-cancellable Operating and Finance Leases	Commitments relating to non-cancellable operating and finance leases as of December 31, 2019 for each of the next five years and thereafter are as follows: Payments due within Operating Leases Finance Leases 1 year $ 506 $ 42 2 years 352 42 3 years 146 42 4 years 103 37 5+ years 222 0 Total minimum future payments 1,329 163 Less: Imputed interest (133 ) (20 ) Total liabilities 1,196 143 Less: Current portion (455 ) (33 ) Long-term liabilities $ 741 $ 110

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Schedule of Contractual Obligations, Commitments and Contingencies	Contractual obligations, commitments and contingencies related to outstanding debt and interest on outstanding debt from continuing operations at December 31, 2019 were as follows: Payments due within: Long-Term Debt Interest on Outstanding Debt 1 year $ 349 $ 16 2 years 35 6 3 years 38 4 4 years 37 1 5+ years 0 0 $ 459 $ 27

Financial Information by Segm_2

Financial Information by Segment (Tables)	6 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment Information	Segment information as of December 31, 2019 and 2018 and for the three and six months then ended is as follows: Healthcare Services Pharmacy Corporate and Other Total As of and for the three months ended December 31, 2019, Net revenues from external customers $ 4,314 $ 8,491 $ 0 $ 12,805 Operating profit (loss) 297 518 (534 ) 281 Depreciation and amortization 89 260 1 350 Assets 7,339 9,892 5,592 22,823 Expenditures for property, plant and equipment 17 280 0 297 As of and for the three months ended December 31, 2018, Net revenues from external customers $ 4,081 $ 8,070 $ 0 $ 12,151 Operating profit (loss) 326 61 (521 ) (134 ) Depreciation and amortization 85 266 0 351 Assets 13,069 8,605 4,052 25,726 Expenditures for property, plant and equipment 59 173 0 232 As of and for the six months ended December 31, 2019, Net revenues from external customers $ 8,546 $ 15,911 $ 0 $ 24,457 Operating profit (loss) 465 781 (1,185 ) 61 Depreciation and amortization 177 506 2 685 Assets 7,339 9,892 5,592 22,823 Expenditures for property, plant and equipment 55 493 0 548 As of and for the six months ended December 31, 2018, Net revenues from external customers $ 7,772 $ 14,586 $ 0 $ 22,358 Operating profit (loss) 110 4 (975 ) (861 ) Depreciation and amortization 166 522 1 689 Assets 13,069 8,605 4,052 25,726 Expenditures for property, plant and equipment 202 442 0 644

Basis of Presentation and Ado_3

Basis of Presentation and Adoption of Recently Issued Accounting Standards - Additional Information (Detail) - USD ($)	Dec. 31, 2019	Jul. 01, 2019	Jun. 30, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Operating lease liabilities	$ 1,196,000
Operating lease ROU assets	$ 1,194,000		$ 0
Accounting Standards Codification ("ASC") 842 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Operating lease liabilities		$ 1,423,000
Operating lease ROU assets		1,423,000
Impact on retained earnings		$ 0

Business Operations - Additiona

Business Operations - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2019SegmentBedaArea
Business And Organization [Line Items]
Number of segments | Segment	2
Healthcare Services Segment [Member] | Mississippi [Member]
Business And Organization [Line Items]
Area of unimproved land owned by subsidiary | a	5
Healthcare Services Segment [Member] | Acute Care Hospital [Member] | Mississippi [Member]
Business And Organization [Line Items]
Number of licensed-bed owned and operated by a subsidiary	84
Number of bed in nursing home owned and operated by subsidiary	66
Number of bed in geriatric psychology subsidiary	18
Pharmacy Segment [Member] | Louisiana [Member]
Business And Organization [Line Items]
Number of operational areas | Area	4

Discontinued Operations - Sched

Discontinued Operations - Schedule of Discontinued Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Net Revenues:
Net revenues	$ 13	$ 2,078	$ 37	$ 3,930
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	(245)	47	(363)	(47)
Income tax expense	0	0	0	0
Earnings (Loss) from discontinued operations	(245)	47	(363)	(47)
Parkside Nursing Home [Member]
Net Revenues:
Net revenues	3	2,072	17	3,917
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	(120)	122	(180)	64
Sold Hospitals [Member]
Net Revenues:
Net revenues	10	6	20	13
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	(82)	(51)	(115)	(62)
Life Sciences and Engineering [Member]
Earnings (Loss) before income taxes:
Earnings (Loss) before income taxes	$ (43)	$ (24)	$ (68)	$ (49)

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 17, 2019	Dec. 31, 2019	Jun. 30, 2019
Parkside Nursing Home [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale	$ 7,300
Pre-tax gain on the sale			$ 2,136
Life Sciences and Engineering [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contribution to pension plan		$ 66
Expected contribution to pension plan during the remaining fiscal year		$ 66

Discontinued Operations - Compo

Discontinued Operations - Components of Pension Expense (Detail) - Life Sciences and Engineering [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Type [Extensible List]	us-gaap:PensionPlansDefinedBenefitMember	us-gaap:PensionPlansDefinedBenefitMember	us-gaap:PensionPlansDefinedBenefitMember	us-gaap:PensionPlansDefinedBenefitMember
Interest Cost	$ 10	$ 14	$ 24	$ 28
Expected return on assets	(8)	(9)	(17)	(18)
Amortization of prior service cost	41	19	61	39
Net pension expense	$ 43	$ 24	$ 68	$ 49

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($)	Feb. 13, 2020	Dec. 31, 2019	Oct. 03, 2019	Dec. 13, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Oct. 08, 2019	Nov. 29, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock repurchased during period, shares							3,814	359,959
Share-based compensation, amount recognized					$ 0	$ 0	$ 27,000	$ 1,000
2011 Director Stock Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted							50,000	0
Subsequent Event [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock repurchased during period, shares	8,086
Stock repurchased during period, value	$ 9,000
2019-2020 Common Share Repurchase Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock repurchased during period, shares		3,814
Stock repurchased during period, value		$ 4,000
2018 Common Share Repurchase Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock repurchased during period, shares			359,959	300,000
Additional shares authorized for purchase				450,000
Stock repurchased during period value excluding fees and expenses			$ 372,000
Maximum [Member] | 2019-2020 Common Share Repurchase Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Amount of shares authorized to be repurchased									$ 750,000
Maximum [Member] | 2018 Common Share Repurchase Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized to be repurchased										300,000

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Total Share Repurchased and Average Price Per Share Paid for the Program (Detail) - $ / shares	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Purchased	3,814	359,959
Average Price Per Share Paid	$ 1.17	$ 1.03
November 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Purchased	935
Average Price Per Share Paid	$ 1.17
December 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Purchased	2,879
Average Price Per Share Paid	$ 1.18
November 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Purchased		1,235
Average Price Per Share Paid		$ 1.14
December 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Purchased		358,724
Average Price Per Share Paid		$ 1.03

Revenue and Accounts Receivab_3

Revenue and Accounts Receivables - Summary of Revenue by Payor (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	$ 12,805	$ 12,151	$ 24,457	$ 22,358
Medicare [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	5,295	3,372	10,359	7,582
Medicaid [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	4,061	5,149	7,244	8,147
Retail and Institutional Pharmacy [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	1,442	1,642	3,141	3,275
Managed Care & Other Insurance [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	1,877	1,751	3,396	2,872
Self-Pay [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	90	185	238	384
Rent [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	8	16	18	30
Other [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Net Revenues	$ 32	$ 36	$ 61	$ 68

Revenue and Accounts Receivab_4

Revenue and Accounts Receivables - Summary Information for Accounts Receivable (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 6,275		$ 5,230
Less allowance for concession adjustments	(648)	$ (462)	(515)	$ (459)	$ (451)	$ (529)
Patient and customer accounts receivable - net	$ 5,627		$ 4,715

Revenue and Accounts Receivab_5

Revenue and Accounts Receivables - Summary of Allowance for Concession Adjustments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Revenue Reconciling Item [Line Items]
Beginning balance	$ 462	$ 451	$ 515	$ 529
Accounts written off, net of recoveries	(332)	(199)	(477)	(408)
Ending balance	648	459	648	459
Continuing Operations [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Additions recognized as a reduction to revenues	532	222	644	372
Discontinued Operations [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Additions recognized as a reduction to revenues	(14)	(15)	(34)	(34)
Healthcare Services Segment [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Beginning balance	286	185	331	253
Accounts written off, net of recoveries	(240)	(65)	(314)	(161)
Ending balance	393	231	393	231
Healthcare Services Segment [Member] | Continuing Operations [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Additions recognized as a reduction to revenues	361	126	410	173
Healthcare Services Segment [Member] | Discontinued Operations [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Additions recognized as a reduction to revenues	(14)	(15)	(34)	(34)
Pharmacy Segment [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Beginning balance	176	266	184	276
Accounts written off, net of recoveries	(92)	(134)	(163)	(247)
Ending balance	255	228	255	228
Pharmacy Segment [Member] | Continuing Operations [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Additions recognized as a reduction to revenues	171	96	234	199
Pharmacy Segment [Member] | Discontinued Operations [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Additions recognized as a reduction to revenues	$ 0	$ 0	$ 0	$ 0

Intangible Assets - Intangible

Intangible Assets - Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Indefinite-lived Intangible Assets [Line Items]
Total	$ 1,295	$ 1,353
Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	2,892	2,892
Accumulated Amortization	(1,597)	(1,539)
Total	1,295	1,353
Trade Name [Member] | Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets	1,180	1,180
Customer Relationships [Member] | Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] | Specialty Pharmacy Segment [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 623	$ 623

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 29	$ 29	$ 58	$ 58

Long-Term Debt - Summary of Lon

Long-Term Debt - Summary of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Debt Instrument [Line Items]
Capital Lease	$ 143	$ 159
Less unamortized debt issuance costs	(22)	(195)
Less current maturities	(327)	(2,836)
Long-term Debt	110	127
Trace RDA Loan [Member]
Debt Instrument [Line Items]
Trace RDA Loan	$ 316	$ 2,999

Long-Term Debt (Trace RDA Loan)

Long-Term Debt (Trace RDA Loan) - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 07, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Prepayment of loan				$ 2,698	$ 138
Non-cash loss on early extinguishment of debt		$ 160	$ 0	$ 160	$ 0
Trace RDA Loan [Member]
Debt Instrument [Line Items]
Debt instrument maturity period				15 years
Debt instrument description				prime rate (as published in the Wall Street Journal) plus 1% with a floor of 5.5%
Debt instrument interest rate, basis spread				1.00%
Debt instrument, interest rate floor		5.50%		5.50%
Effective interest rate		5.75%		5.75%
Prepayment of loan	$ 2,500
Non-cash loss on early extinguishment of debt		$ 160		$ 160
Outstanding loan repayment date				2020-10
Trace RDA Loan [Member] | Mortgages [Member]
Debt Instrument [Line Items]
Loan agreement amount		$ 9,975		$ 9,975
Date of loan agreement				Jul. 5, 2012

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 0	$ 0	$ 0	$ 0
Federal tax expense (benefit)	0	0	0	0
State tax expense (benefit)	0	$ 0	0	$ 0
Deferred income tax valuation allowance	8,674,000		8,674,000
Net long-term deferred income tax asset or liability	0		0
Net operating loss carry-forward	$ 19,200,000		$ 19,200,000
Net operating loss carryforward expiration year			2023 through fiscal 2038

Lease - Components of Lease Cos

Lease - Components of Lease Cost and Rent Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2019
Operating lease cost:
Operating lease cost	$ 143	$ 290
Short-term rent expense	4	15
Variable lease cost	0	1
Total operating lease cost	147	306
Finance lease cost:
Amortization right-of-use assets	9	18
Interest on finance lease liabilities	2	5
Total finance lease cost	$ 11	$ 23

Lease - Summary of Supplemental

Lease - Summary of Supplemental Balance Sheet Information to Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Operating Leases:
Operating Lease ROU Assets	$ 1,194	$ 0
Finance Leases:
Finance Lease ROU Assets	$ 203
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:PropertyPlantAndEquipmentNet
Accumulated amortization	$ 29
Current finance lease liabilities	$ 33
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:LongTermDebtCurrent
Long-term finance lease liabilities	$ 110
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:LongTermDebtNoncurrent

Lease - Summary of Supplement_2

Lease - Summary of Supplemental Cash Flow and Other Information Related to Leases (Detail) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 150	$ 289
Operating cash flows from finance leases	2	5
Financing cash flow from finance leases	8	16
Right-of-use assets obtained in exchange for new finance lease liabilities	0	0
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 9	$ 1,448
Weighted-average remaining lease term:
Operating leases	3 years 10 months 28 days	3 years 10 months 28 days
Finance leases	3 years 9 months 7 days	3 years 9 months 7 days
Weighted-average discount rate:
Operating leases	6.54%	6.54%
Finance leases	5.53%	5.53%

Lease - Summary of Non-cancella

Lease - Summary of Non-cancellable Operating and Finance Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2019
Leases [Abstract]
1 year	$ 506
2 years	352
3 years	146
4 years	103
5+ years	222
Total minimum future payments	1,329
Less: Imputed interest	(133)
Total liabilities	1,196
Less: Current portion	(455)	$ 0
Long-term liabilities	741	$ 0
1 year	42
2 years	42
3 years	42
4 years	37
5+ years	0
Total minimum future payments	163
Less: Imputed interest	(20)
Total liabilities	143
Less: Current portion	(33)
Long-term finance lease liabilities	$ 110

Accrued Sales Tax - Additional

Accrued Sales Tax - Additional Information (Details) $ in Thousands	6 Months Ended
	Dec. 31, 2019USD ($)Authority	Jun. 30, 2019USD ($)
Payables And Accruals [Abstract]
Number of taxing authorities | Authority	2
Sales tax accrued	$ 1,132	$ 843
Estimable and probable collection recorded	$ 267

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contingencies (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due within 1 year	$ 349
Payments due within 2 years	35
Payments due within in 3 years	38
Payments due within 4 years	37
Payments due within 5+ years	0
Contractual obligations, commitments and contingencies	459
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due within 1 year	16
Payments due within 2 years	6
Payments due within in 3 years	4
Payments due within 4 years	1
Payments due within 5+ years	0
Contractual obligations, commitments and contingencies	$ 27

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Management [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Related Party Transaction [Line Items]
Legal services to these law firms	$ 62	$ 59	$ 180	$ 135
Amount payable to law firms	$ 19		$ 19		$ 47

Asset Sales - Additional Inform

Asset Sales - Additional Information (Detail) $ in Thousands	Dec. 20, 2019USD ($)a	Sep. 09, 2019USD ($)a	Oct. 11, 2018USD ($)a	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Asset Sales [Line Items]
Pre-tax gain on the sale of property				$ 86	$ 452	$ 193	$ 454
Undeveloped Land [Member] | Fulton, MO [Member]
Asset Sales [Line Items]
Undeveloped land sold | a		11.4
Proceeds from sale		$ 348
Pre-tax gain on the sale of property						100
Medical Office Building [Member] | Clanton, AL [Member]
Asset Sales [Line Items]
Undeveloped land sold | a	4
Proceeds from sale	$ 204
Pre-tax gain on the sale of property				$ 86		$ 86
Medical Office Building And Undeveloped Land [Member] | Dahlonega, GA [Member]
Asset Sales [Line Items]
Undeveloped land sold | a			2
Proceeds from sale			$ 935
Pre-tax gain on the sale of property					$ 452		$ 452

Land Acquisition - Additional I

Land Acquisition - Additional Information (Detail) - Promissory Note [Member] - Land $ in Thousands	6 Months Ended
	Dec. 31, 2019a	Nov. 01, 2019USD ($)	Sep. 30, 2019USD ($)
Business Acquisition [Line Items]
Promissory note receivable term	5 years
Promissory note maturity date	2019-10
Area of real property non-recourse mortgaged for notes receivable | a	24.74
Real property conveyed date	Nov. 1, 2019
Estimated value of the note receivable			$ 371
Value of property at conveyance		$ 371

Financial Information by Segm_3

Financial Information by Segment - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2019Segment
Segment Reporting [Abstract]
Number of segments	2

Financial Information by Segm_4

Financial Information by Segment - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 12,805	$ 12,151	$ 24,457	$ 22,358
Operating profit (loss)	281	(134)	61	(861)
Depreciation and amortization	350	351	685	689
Assets	22,823	25,726	22,823	25,726	$ 24,419
Expenditures for property, plant and equipment	297	232	548	644
Operating Segments [Member] | Healthcare Services Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	4,314	4,081	8,546	7,772
Operating profit (loss)	297	326	465	110
Depreciation and amortization	89	85	177	166
Assets	7,339	13,069	7,339	13,069
Expenditures for property, plant and equipment	17	59	55	202
Operating Segments [Member] | Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	8,491	8,070	15,911	14,586
Operating profit (loss)	518	61	781	4
Depreciation and amortization	260	266	506	522
Assets	9,892	8,605	9,892	8,605
Expenditures for property, plant and equipment	280	173	493	442
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	0	0	0	0
Operating profit (loss)	(534)	(521)	(1,185)	(975)
Depreciation and amortization	1	0	2	1
Assets	5,592	4,052	5,592	4,052
Expenditures for property, plant and equipment	$ 0	$ 0	$ 0	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Feb. 12, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Prepayment of loan					$ 2,698	$ 138
Non-cash loss on early extinguishment of debt			$ (160)	$ 0	$ (160)	$ 0
Subsequent Event [Member]
Subsequent Event [Line Items]
Prepayment of loan		$ 278
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Non-cash loss on early extinguishment of debt	$ 20